What does a CA-125 test measure and what is its clinical use?

What Does a CA-125 Test Measure?

CA-125 is a blood test that measures a protein (cancer antigen 125) primarily used to evaluate suspected ovarian cancer, monitor treatment response in diagnosed ovarian cancer patients, and detect disease recurrence—though it should never be used alone for screening or diagnosis due to limited specificity.

What CA-125 Measures

CA-125 (also known as mucin 16 or MUC16) is a large membrane glycoprotein produced by normal epithelial tissues including the peritoneum, pleura, and pericardium 1, 2. The test measures serum levels of this antigen, with values ≥35 U/mL generally considered elevated 1, 3.

Primary Clinical Uses

1. Preoperative Evaluation of Suspected Ovarian Cancer

• Elevated in ~85% of advanced ovarian cancer cases but only ~50% of stage I disease 1, 3
• True-positive rate: 50% for stage I, 80% for stage II or greater 1
• Must be interpreted alongside imaging (transvaginal ultrasound, CT) and clinical findings—never used in isolation 1, 3

Critical caveat: CA-125 has poor specificity in premenopausal women. False-positives occur with:

• Endometriosis
• Benign ovarian cysts
• Pregnancy
• Pelvic inflammatory disease
• Menstruation
• Pancreatic cancer
• Cirrhosis
• Any condition causing peritoneal inflammation 1, 4, 5

The specificity is 98.5% in women >50 years but only 94.5% in women <50 years 4.

2. Monitoring Treatment Response

CA-125 shows very high correlation with clinical course during chemotherapy 1. Serial measurements help assess:

• Response to initial treatment
• Need for treatment modifications
• The CA-125 KELIM (elimination rate constant) calculated over the first 100 days provides prognostic information about likelihood of complete surgical debulking and platinum-resistant relapse 6

3. Surveillance for Recurrence

For patients who achieved complete response with post-treatment CA-125 <35 U/mL:

• CA-125 can predict tumor recurrence in clinically tumor-free patients 1
• Detection rates for recurrence: 62-74% in ovarian cancer 7
• However, routine CA-125 monitoring after first-line treatment should be discussed with patients as an option, not mandated 8, 6

Important evidence: A European trial demonstrated that treating recurrence early based solely on elevated CA-125 (without clinical symptoms) does not improve survival and decreases quality of life 8. Therefore:

• For asymptomatic patients with only biochemical relapse (elevated CA-125 without radiographic/clinical evidence), delaying treatment until clinical symptoms appear is recommended 8
• Progressive elevation over time is more concerning than a single elevated value 4

4. Differentiating Tumor Origin

When combined with other markers:

• High CA-125/CEA ratio (≥25:1) suggests ovarian rather than gastrointestinal primary 1, 3
• CA-19-9 and CEA can be elevated with epithelial ovarian neoplasms but have limited individual specificity 1

What CA-125 Should NOT Be Used For

Screening in Average-Risk Women

• General population screening cannot be recommended because it does not reduce cancer deaths 6
• Even multimodal screening (CA-125 + ultrasound) is not yet the gold standard 4

Sole Diagnostic Tool

• CA-125 with or without HE4 should not be used alone to differentiate benign, borderline, and malignant ovarian tumors 6
• Ultrasound-based models (IOTA Simple Rules, IOTA ADNEX) are superior to CA-125 alone 3

Histological Subtype Considerations

CA-125 utility varies dramatically by tumor histology 9:

• High-grade serous carcinoma: Excellent sensitivity (81.8-93.5%)
• Clear cell and mucinous carcinomas: Poor sensitivity (28.6-66.7%)
• For low-sensitivity subtypes, consider using CA-125 ratio (maximum value during surveillance ÷ post-treatment value) with cutoff ≥1.5 9

Practical Algorithm for CA-125 Interpretation

In suspected ovarian cancer:

1. Measure CA-125 alongside transvaginal ultrasound and CT imaging
2. If elevated in postmenopausal woman with complex ovarian mass → high suspicion for malignancy
3. If elevated in premenopausal woman → consider benign causes first
4. Add CEA and CA-19-9 if mucinous histology suspected

During treatment:

1. Serial measurements every cycle to assess response
2. Consider KELIM calculation for prognostic information

Post-treatment surveillance:

1. Discuss pros/cons of routine CA-125 monitoring with patient
2. If monitoring chosen: quarterly for 2 years, then semiannually 7
3. If elevated without symptoms → delay treatment until clinical evidence appears
4. Progressive elevation more concerning than single value

The key principle: CA-125 is a useful adjunct when interpreted in proper clinical context, but never a standalone diagnostic or screening tool 1, 4, 3.